Bristol-Myers Squibb Valuation
| BMYMP Stock | USD 900.55 0.00 0.00% |
At this time, the firm appears to be overvalued. Bristol Myers Squibb shows a prevailing Real Value of $736.98 per share. The current price of the firm is $900.55. Our model approximates the value of Bristol Myers Squibb from analyzing the firm fundamentals such as Cash Per Share of 3.72 X, revenue of 46.38 B, and Net Income of 7.01 B as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Bristol-Myers Squibb's price fluctuation is very steady at this time. Calculation of the real value of Bristol Myers Squibb is based on 3 months time horizon. Increasing Bristol-Myers Squibb's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Bristol-Myers Squibb's intrinsic value may or may not be the same as its current market price of 900.55, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 900.55 | Real 736.98 | Hype 900.55 | Naive 910.15 |
The intrinsic value of Bristol-Myers Squibb's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bristol-Myers Squibb's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bristol Myers Squibb helps investors to forecast how Bristol-Myers pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bristol-Myers Squibb more accurately as focusing exclusively on Bristol-Myers Squibb's fundamentals will not take into account other important factors: Bristol-Myers Squibb Total Value Analysis
Bristol Myers Squibb is currently expected to have takeover price of 0 with market capitalization of 2.11 T, debt of 39.6 B, and cash on hands of 6.07 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Bristol-Myers Squibb fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 2.11 T | 39.6 B | 6.07 B |
Bristol-Myers Squibb Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Bristol-Myers connotes not a very effective usage of assets in February.Bristol-Myers Squibb Profitability Analysis
The company reported the revenue of 46.38 B. Net Income was 7.01 B with profit before overhead, payroll, taxes, and interest of 0.About Bristol-Myers Squibb Valuation
The pink sheet valuation mechanism determines Bristol-Myers Squibb's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Bristol Myers Squibb based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bristol-Myers Squibb. We calculate exposure to Bristol-Myers Squibb's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bristol-Myers Squibb's related companies.Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.
8 Steps to conduct Bristol-Myers Squibb's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Bristol-Myers Squibb's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bristol-Myers Squibb's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Bristol-Myers Squibb's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Bristol-Myers Squibb's revenue streams: Identify Bristol-Myers Squibb's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Bristol-Myers Squibb's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Bristol-Myers Squibb's growth potential: Evaluate Bristol-Myers Squibb's management, business model, and growth potential.
- Determine Bristol-Myers Squibb's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bristol-Myers Squibb's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Bristol-Myers Squibb Growth Indicators
Investing in growth stocks can be very risky. If the company such as Bristol-Myers Squibb does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.6 B | |
| Retained Earnings | 23.8 B | |
| Retained Earnings Total Equity | 23.8 B |
Additional Tools for Bristol-Myers Pink Sheet Analysis
When running Bristol-Myers Squibb's price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.